Answers are grounded in this paper and cite their sources.
Introduction. The SARS-CoV-2 virus, which emerged in 2019, continues to circulate globally. New genetic variants of the virus continue to arise, including recombinant forms. Continuous epidemiological surveillance is essential to track circulating and emerging variants, with high-throughput sequencing serving as a primary method for investigating the genetic variability and prevalence of circulating SARS-CoV-2 variants. Objective. The aim of this study was to analyze the dynamics of prevalence of various SARS-CoV-2 genetic variants across 12 regions of the Russian Federation from January 2024 to February 2026. Specific objectives included identification of dominant variants, assessment of trends in SARS-CoV-2 genetic diversity, and evaluation of time intervals between the first globally documented cases of new genetic variants and their initial detection within the Russian Federation. Materials and Methods. The workflow comprised nucleic acid extraction from collected specimens, reverse transcription, polymerase chain reaction (PCR), real-time PCR (qPCR), purification of amplification products, nucleic acid quantification, library preparation for next-generation sequencing, and whole-genome sequence analysis. Results. A total of 4 640 samples collected between January 2024 and February 2026 from 12 regions of the Russian Federation were analyzed. Genetic diversity of circulating SARS-CoV-2 variants decreased by more than 1.8-fold compared to 2024 levels (134 versus 73 variants, respectively), with the novel recombinant variant XFG predominating. The time lag between the first globally documented cases of new genetic variants and their initial detection across the 12 regions ranged from 1 to 10 months. Conclusion. Analysis of nucleotide sequences revealed a significant reduction in the genetic diversity of circulating SARS-CoV-2 variants between January 2024 and February 2026. The reduction in the genetic diversity of circulating SARS-CoV-2 variants, coupled with a sharp increase in the proportion of the recombinant variant XFG and its derivatives (XFG.3, XFG.3.1, and others) since June 2025, suggests that this recombinant lineage will predominate over the subsequent period (through the end of 2026). Variability in the time intervals between global and Russian Federation detection of new genetic variants may be attributed not only to imported cases but also to limited surveillance coverage and predominant sampling from patients with severe disease. Timely identification of emerging and potentially hazardous variants, accurate assessment of their prevalence, and evidence-based adjustments to prevention strategies are feasible only through the integration of traditional diagnostic methods with high-throughput sequencing.
No takes yet. Share an insight, caveat, or question.
Mokronosov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: